Abrdn Life Sciences Investors Past Earnings Performance
Past criteria checks 1/6
There is insufficient data on Abrdn Life Sciences Investors's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Capital Markets Industry Growth | 10.3% |
| Revenue growth rate | 34.4% |
| Return on equity | 1.3% |
| Net Margin | 156.5% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
HQL: Hold Your Investments In This Healthcare CEF For Strong, Steady Yield
Sep 27HQL: 13% Discount Creates An Opportunity
Jun 29Tekla Life Sciences raises dividend by 6.5% to $0.33
Feb 15Tekla Life Sciences declines quarterly dividend by -11.4% to $0.31/share
Nov 16Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV
Oct 23HQL: A Biotechnology Equity CEF With No Leverage
Jul 12HQL: Buy For The Yield, If You Can Stomach The Depreciation
Apr 27Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend
Feb 11Tekla Life Sciences Investors Rides Biotechnology Wave, Offers Growth With Steady Income
Sep 22Evaluating Closed-End Funds: HQL Is Another Fine Pick In A Hot Sector
Jun 29Tekla Life Sciences Investors: 8% Yield, 7% Discount
Jan 09Tekla Life Sciences declares $0.02 special dividend
Dec 21Tekla Life Sciences declares $0.40 dividend
Nov 16Revenue & Expenses BreakdownBeta
How Abrdn Life Sciences Investors makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 4 | 5 | 6 | 0 |
| 31 Dec 22 | 3 | -50 | 6 | 0 |
| 30 Sep 22 | 3 | -105 | 6 | 0 |
| 30 Jun 22 | 3 | -74 | 6 | 0 |
| 31 Mar 22 | 3 | -43 | 6 | 0 |
| 31 Dec 21 | 2 | 11 | 6 | 0 |
| 30 Sep 21 | 2 | 65 | 6 | 0 |
| 30 Jun 21 | 2 | 94 | 6 | 0 |
| 31 Mar 21 | 2 | 124 | 6 | 0 |
| 31 Dec 20 | 3 | 124 | 6 | 0 |
| 30 Sep 20 | 3 | 123 | 6 | 0 |
| 30 Jun 20 | 3 | 61 | 5 | 0 |
| 31 Mar 20 | 3 | -1 | 5 | 0 |
| 31 Dec 19 | 3 | -36 | 5 | 0 |
| 30 Sep 19 | 2 | -70 | 5 | 0 |
| 30 Jun 19 | 2 | -31 | 5 | 0 |
| 31 Mar 19 | 2 | 9 | 6 | 0 |
| 31 Dec 18 | 2 | 19 | 6 | 0 |
| 30 Sep 18 | 2 | 29 | 6 | 0 |
| 30 Jun 18 | 2 | 25 | 6 | 0 |
| 31 Mar 18 | 2 | 22 | 6 | 0 |
| 31 Dec 17 | 2 | 45 | 6 | 0 |
| 30 Sep 17 | 2 | 69 | 6 | 0 |
| 30 Jun 17 | 2 | 76 | 5 | 0 |
| 31 Mar 17 | 2 | 84 | 5 | 0 |
| 31 Dec 16 | 1 | 36 | 5 | 0 |
| 30 Sep 16 | 1 | -12 | 5 | 0 |
| 30 Jun 16 | 1 | -66 | 6 | 0 |
| 31 Mar 16 | 2 | -120 | 6 | 0 |
| 31 Dec 15 | 1 | -40 | 6 | 0 |
| 30 Sep 15 | 1 | 40 | 6 | 0 |
| 30 Jun 15 | 1 | 93 | 6 | 0 |
| 31 Mar 15 | 1 | 145 | 5 | 0 |
| 31 Dec 14 | 1 | 117 | 5 | 0 |
| 30 Sep 14 | 1 | 89 | 5 | 0 |
| 30 Jun 14 | 1 | 92 | 4 | 0 |
| 31 Mar 14 | 1 | 94 | 4 | 0 |
| 31 Dec 13 | 1 | 89 | 4 | 0 |
| 30 Sep 13 | 1 | 85 | 4 | 0 |
| 30 Jun 13 | 1 | 67 | 4 | 0 |
Quality Earnings: HQL has a large one-off gain of $7.5M impacting its last 12 months of financial results to 31st March, 2023.
Growing Profit Margin: HQL became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if HQL's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: HQL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: HQL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Capital Markets industry (3.3%).
Return on Equity
High ROE: HQL's Return on Equity (1.3%) is considered low.